Research supported by UK Kidney Association registries will feature across multiple sessions at the 2026 Congress of the European Renal Association (ERA) in Glasgow, highlighting the role of UK data in advancing kidney research at an international level.
RaDaR: rare kidney disease research on the international stage
Work from the National Registry of Rare Kidney Diseases (RaDaR) will be presented across the Congress, including work from research fellows and statisticians.
Dr Katie Wong, RaDaR Clinical Research Fellow at the UK Renal Registry, will present work on Alport syndrome, examining associations between genotype, proteinuria and kidney outcomes using longitudinal UK registry data. Her abstract has been recognised within the ERA Top and Best Abstracts selection as one of the Best Abstracts presented by young authors.
5 June, 16:00–17:00, M1 Room
RaDaR data will also feature in a session led by Dr Lexy Sorrell, RaDaR Statistician, “Real-world clinical profile, treatment patterns and outcomes associated with C3G and primary IC-MPGN: insights from the UK RaDaR registry”.
4 June, 11:15–12:45, Forth Room
In addition, Dr Sapna Shah will present “The Financial and Environmental Cost of Post-Kidney Transplant CMV Infection in the UK”. This work includes significant contributions from RaDaR Biostatistician David Pitcher, reflecting the role of the RaDaR team in supporting robust analysis across kidney research.
4 June, 16:00–17:00, Focussed Oral Room 11
Together, these presentations demonstrate the breadth of research enabled by RaDaR, from rare disease characterisation to outcomes research and health economics.
RaDaR is the UK’s national registry for rare kidney conditions and the largest of its kind globally, bringing together longitudinal data from over 35,000 patients across more than 100 sites. It supports a wide range of research, from natural history studies and biomarker validation to trial readiness and regulatory engagement.
UK Renal Registry: national data informing service delivery and collaborative research
Research supported by the UK Renal Registry (UKRR) will also be presented at ERA 2026, demonstrating how national data can inform service planning, clinical practice and patient care.
Dr Nithin Bodapati, UK Renal Registry Clinical Fellow, will present:
“Trends and Variations in Peritoneal Dialysis Technique Failure in the UK: Implications for Dialysis Service Capacity”
4 June 2026, 12:10, Focussed Oral Room 8
Using UKRR data, this work shows that around 1 in 5 patients on peritoneal dialysis transfer to haemodialysis each year due to technique failure, with variation between centres. The findings highlight how strengthening peritoneal dialysis services could support patient choice while helping to protect haemodialysis capacity.
UKRR-supported research will also be presented through NEPHwork, a UKKA-led collaborative research network that brings together clinicians and centres across the UK to deliver large-scale, multi-site studies using real-world data.
As part of the scientific programme, Dr Sacha Moore will present:
“Complications and Consent Practices in Native Kidney Biopsy: Insights from the IGNITE Study of >1700 Procedures”
4 June 2026, 17:57, Focussed Oral Room 6
The study, co-authored by Dr Bodapati, analyses data from over 1,700 kidney biopsies to provide insight into complications and consent practices across UK centres, demonstrating the value of coordinated, registry-enabled collaboration in understanding variation in care and improving clinical practice.
UKKA registries enabling internationally recognised research
Across both RaDaR and the UK Renal Registry, these presentations reflect the scale and maturity of the UKKA’s national data infrastructure.
By bringing together longitudinal data from across the UK, UKKA registries enable research that would not be possible at a single-centre level - from rare disease discovery to service evaluation and health system planning.
Their presence across multiple sessions at ERA 2026 highlights the growing international relevance of UK registry-led research and its role in informing clinical practice, shaping services and supporting the development of new treatments.